Literature DB >> 23773266

Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012.

Shigenobu Kanba1, Tadafumi Kato, Takeshi Terao, Kazuo Yamada.   

Abstract

The Japanese Society of Mood Disorders established a committee for treatment guidelines of mood disorders, which created the first edition of a treatment guideline for bipolar disorders on 10 March 2011. The committee has now created a second edition, which we report here. In creating this treatment guideline, the first step was to have several bipolar disorder specialists review well-conducted studies and meta-analyses. Based on this evidence, and with a consensus among the specialists, treatment procedures that were considered optimal were compiled and the strength of recommendation for each treatment method was determined. The first draft, prepared in this manner, was further revised through a process of critical investigation by all committee members to produce the final edition.
© 2013 The Authors. Psychiatry and Clinical Neurosciences © 2013 Japanese Society of Psychiatry and Neurology.

Entities:  

Keywords:  antidepressants; bipolar disorders; guidelines; mood stabilizer

Mesh:

Substances:

Year:  2013        PMID: 23773266     DOI: 10.1111/pcn.12060

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  12 in total

Review 1.  Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder.

Authors:  Jose de Leon; Edoardo Spina
Journal:  Curr Psychiatry Rep       Date:  2018-03-12       Impact factor: 5.285

2.  The influence of psychoeducation on regulating biological rhythm in a sample of patients with bipolar II disorder: a randomized clinical trial.

Authors:  Augusto Duarte Faria; Luciano Dias de Mattos Souza; Taiane de Azevedo Cardoso; Karen Amaral Tavares Pinheiro; Ricardo Tavares Pinheiro; Ricardo Azevedo da Silva; Karen Jansen
Journal:  Psychol Res Behav Manag       Date:  2014-06-26

3.  Effectiveness of Simple Individual Psychoeducation for Bipolar II Disorder.

Authors:  Yuka Saito-Tanji; Emi Tsujimoto; Reiko Taketani; Ami Yamamoto; Hisae Ono
Journal:  Case Rep Psychiatry       Date:  2016-07-31

4.  Prevalence of Therapeutic Drug Monitoring for Lithium and the Impact of Regulatory Warnings: Analysis Using Japanese Claims Database.

Authors:  Nobuhiro Ooba; Daisuke Tsutsumi; Naoko Kobayashi; Shinji Hidaka; Hiroyuki Hayashi; Taku Obara; Michihiro Satoh; Kiyoshi Kubota; Noriyasu Fukuoka
Journal:  Ther Drug Monit       Date:  2018-04       Impact factor: 3.681

5.  Utility of TEMPS-A in differentiation between major depressive disorder, bipolar I disorder, and bipolar II disorder.

Authors:  Chihiro Morishita; Rie Kameyama; Hiroyuki Toda; Jiro Masuya; Masahiko Ichiki; Ichiro Kusumi; Takeshi Inoue
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

6.  Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.

Authors:  Mitsukuni Murasaki; Tsukasa Koyama; Shigenobu Kanba; Masahiro Takeuchi; Yuriko Shimizu; Eri Arita; Kentaro Kuroishi; Masahiro Takeuchi; Shinya Kamei
Journal:  Psychopharmacology (Berl)       Date:  2018-08-01       Impact factor: 4.530

7.  Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.

Authors:  Shigenobu Kanba; Mitsukuni Murasaki; Tsukasa Koyama; Masahiro Takeuchi; Yuriko Shimizu; Eri Arita; Kentaro Kuroishi; Masahiro Takeuchi; Shinya Kamei
Journal:  BMC Psychiatry       Date:  2019-06-26       Impact factor: 3.630

8.  Evaluation of clarity of presentation and applicability of monitoring instructions for patients using lithium in clinical practice guidelines for treatment of bipolar disorder.

Authors:  M Nederlof; R W Kupka; A M Braam; Acg Egberts; E R Heerdink
Journal:  Bipolar Disord       Date:  2018-08-13       Impact factor: 6.744

9.  Ant1 mutant mice bridge the mitochondrial and serotonergic dysfunctions in bipolar disorder.

Authors:  Tomoaki M Kato; Mie Kubota-Sakashita; Noriko Fujimori-Tonou; Fumihito Saitow; Satoshi Fuke; Akira Masuda; Shigeyoshi Itohara; Hidenori Suzuki; Tadafumi Kato
Journal:  Mol Psychiatry       Date:  2018-06-11       Impact factor: 15.992

10.  Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI).

Authors:  Takashi Tsuboi; Takefumi Suzuki; Takaharu Azekawa; Naoto Adachi; Hitoshi Ueda; Kouji Edagawa; Eiichi Katsumoto; Yukihisa Kubota; Eiichiro Goto; Seiji Hongo; Yoichiro Watanabe; Masaki Kato; Norio Yasui-Furukori; Reiji Yoshimura; Atsuo Nakagawa; Toshiaki Kikuchi; Koichiro Watanabe
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-31       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.